TY  - GEN 
AU  - ABOU JOKH CASAS, ESTEPHANY
AU  - Pubul Nuñez, Virginia
AU  - Anido Herranz, Urbano
AU  - Mallón Araujo, María del Carmen
AU  - Del Pombo Pasín, Maria Carmen
AU  - Garrido Pumar, Miguel
AU  - Cabezas Agrícola, José Manuel
AU  - Cameselle Teijeiro, Jose Manuel
AU  - Hilal, A.
AU  - Ruibal Morell, Alvaro
PY  - 2020
SN  - 1007-9327
UR  - http://hdl.handle.net/20.500.11940/16456
AB  - BACKGROUND: (177)Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine...
KW  - Intestinal Neoplasms
KW  - Stomach Neoplasms
KW  - Proportional Hazards Models
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Grading
KW  - Octreotide
KW  - Survival Rate
KW  - Humans
KW  - Treatment Outcome
KW  - Neuroendocrine Tumors
KW  - Pancreatic Neoplasms
KW  - Aged
KW  - Prognosis
TI  - Evaluation of Lu-177-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
DO  - 10.3748/wjg.v26.i13.1513
KW  - CHUS
VL  - 26
ER  -